相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Abstract B137: Pharmacokinetics and pharmacodynamic biomarkers for the dual PI3K/mTOR inhibitor GDC-0980: Initial phase I evaluation
A. J. Wagner et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Abstract C62: Identification of GSK2126458, a highly potent inhibitor of phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR)
S. D. Knight et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Abstract C197: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors
N. Faulkner et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status: In silico and Biological Evaluations
Shingo Dan et al.
CANCER RESEARCH (2010)
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39
Dexin Kong et al.
EUROPEAN JOURNAL OF CANCER (2010)
Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest
Shingo Dan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Effect of ZSTK474, a Novel Phosphatidylinositol 3-Kinase Inhibitor, on DNA-Dependent Protein Kinase
Dexin Kong et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2009)
Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
Douglas W. McMillin et al.
CANCER RESEARCH (2009)
In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Klaus P. Hoeflich et al.
CLINICAL CANCER RESEARCH (2009)
Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors
Dexin Kong et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor
Dexin Kong et al.
EUROPEAN JOURNAL OF CANCER (2009)
Novel inhibitors of the PI3K family
Amancio Carnero
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
A novel potent and selective inhibitor of PI3K/mTOR, GDC-0980, currently in phase I clinical trials
Lori S. Friedman et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Florence I. Raynaud et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Anthony C. Faber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The regulation and function of Class III PI3Ks: novel roles for Vps34
Jonathan M. Backer
BIOCHEMICAL JOURNAL (2008)
Targeting phosphoinositide 3-kinase - Moving towards therapy
Romina Marone et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2008)
UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers
Sun-Young Kong et al.
CANCER SCIENCE (2008)
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
Jaclyn LoPiccolo et al.
DRUG RESISTANCE UPDATES (2008)
Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation
P. LoRusso et al.
EJC SUPPLEMENTS (2008)
A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors
B. Markman et al.
EJC SUPPLEMENTS (2008)
A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors
E. Calvo et al.
EJC SUPPLEMENTS (2008)
The multiple roles of PtdIns(4)P -: not just the precursor of PtdIns(4,5)P2
Giovanni D'Angelo et al.
JOURNAL OF CELL SCIENCE (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
The PTEN-PI3K pathway: of feedbacks and cross-talks
A. Carracedo et al.
ONCOGENE (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
PTEN-deficient cancers depend on PIK3CB
Susan Wee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Evaluation of action mechanisms of toxic chemicals using JFCR39, a panel of human cancer cell lines
Noriyuki Nakatsu et al.
MOLECULAR PHARMACOLOGY (2007)
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms
Dexin Kong et al.
CANCER SCIENCE (2007)
PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
Christian Rommel et al.
NATURE REVIEWS IMMUNOLOGY (2007)
The NCI60 human tumour cell line anticancer drug screen
Robert H. Shoemaker
NATURE REVIEWS CANCER (2006)
Phosphatidylinositol 4-kinases: old enzymes with emerging functions
Andras Balla et al.
TRENDS IN CELL BIOLOGY (2006)
A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling
Zachary A. Knight et al.
CELL (2006)
Antitumor activity of ZSTK474, a new phosphatidylitiositol 3-kinase inhibitor
Shin-ichi Yaguchi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines
DB Whyte et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
A pharmacological map of the PI3-K family defines a role for p110 alpha in insulin signaling
Zachary A. Knight et al.
CELL (2006)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Mammalian target of rapamycin as a therapeutic target in leukemia
FJ Giles et al.
CURRENT MOLECULAR MEDICINE (2005)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
SY Sun et al.
CANCER RESEARCH (2005)
PI 3-kinase p110β:: a new target for antithrombotic therapy
SP Jackson et al.
NATURE MEDICINE (2005)
Frequent mutation of the PIK3CA gene in ovarian and breast cancers
DA Levine et al.
CLINICAL CANCER RESEARCH (2005)
Signalling by PI3K isoforms: insights from gene-targeted mice
B Vanhaesebroeck et al.
TRENDS IN BIOCHEMICAL SCIENCES (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
HG Wendel et al.
NATURE (2004)
Pladienolides, new substances from culture of Streptomyces platensis Mer-11107 III.: In vitro and In vivo antitumor activities
Y Mizui et al.
JOURNAL OF ANTIBIOTICS (2004)
Defective dendritic cell migration and activation of adaptive immunity in PI3Kγ-deficient mice
A Del Prete et al.
EMBO JOURNAL (2004)
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins
LS Harrington et al.
JOURNAL OF CELL BIOLOGY (2004)
Mutation of the PIK3CA gene in ovarian and breast cancer
IG Campbell et al.
CANCER RESEARCH (2004)
Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1α, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling
HD Skinner et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Mechanisms and implications of phosphoinositide 3-kinase δ in promoting neutrophil trafficking into inflamed tissue
KD Puri et al.
BLOOD (2004)
Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics
T Yamori
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Role of Rab5 in the recruitment of hVps34/p150 to the early endosome
JT Murray et al.
TRAFFIC (2002)
Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine
EH Walker et al.
MOLECULAR CELL (2000)
Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation
E Hirsch et al.
SCIENCE (2000)
分享论文
